Insight into prostate cancer osteolytic metastasis by RelB coordination of IL-8 and S100A4

Abstract

	•RelB activates inflammatory signalling by upregulating IL-8 and suppressing AR.
	•RelB upregulates S100A4 by cooperating with NFATC1.
	•IL-8 boosts EMT by activating Snail 1 and Twist 1, and S100A4 exacerbates osteolytic metastasis via calcium consumption.
	•RelB harnesses IL-8 and S100A4 to drive PCa osteolytic metastasis.

Keywords

IL-8 / osteolytic metastasis / prostate cancer / RelB / S100A4

References

[1] BerishRB, AliAN, TelmerPG, Ronald JA, LeongHS. Translational models of prostate cancer bone metastasis. Nat Rev Urol. 2018; 15: 403-421.

[2] D’OronzoS, WoodS, BrownJE. The use of bisphosphonates to treat skeletal complications in solid tumours. Bone. 2021; 147: 115907.

[3] HofmanMS, Lawrentschuk N, FrancisRJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020; 395: 1208-1216.

[4] GartrellBA, SaadF. Managing bone metastases and reducing skeletal related events in prostate cancer. Nat Rev Clin Oncol. 2014; 11: 335-345.

[5] PolavaramNS, DuttaS, IslamR, et al. Tumor-and osteoclast-derived NRP2 in prostate cancer bone metastases. Bone Res. 2021; 9: 24.

[6] ColemanRE, Croucher PI, PadhaniAR, et al. Bone metastases. Nature Rev Dis Primers. 2020; 6: 83.

[7] InfanteM, FabiA, CognettiF, Gorini S, CaprioM, FabbriA. RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives. J Exp Clin Cancer Res. 2019; 38: 12.

[8] NakaiY, Okamoto K, TerashimaA, et al. Efficacy of an orally active small-molecule inhibitor of RANKL in bone metastasis. Bone Res. 2019; 7: 1.

[9] DougallWC. Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis. Clin Cancer Res. 2012; 18: 326-335.

[10] PapachristouDJ, BasdraEK, PapavassiliouAG. Bone metastases: molecular mechanisms and novel therapeutic interventions. Med Res Rev. 2012; 32: 611-636.

[11] WongSK, Mohamad NV, GiazeTR, ChinKY, Mohamed N, Ima-NirwanaS. Prostate cancer and bone metastases: the underlying mechanisms. Int J Mol Sci. 2019; 20: 2587.

[12] HaraT, Miyazaki H, LeeA, TranCP, ReiterRE. Androgen receptor and invasion in prostate cancer. Cancer Res. 2008; 68: 1128-1135.

[13] LabrecqueMP, BrownLG, ColemanIM, et al. RNA splicing factors SRRM3 and SRRM4 distinguish molecular phenotypes of castration-resistant neuroendocrine prostate cancer. Cancer Res. 2021; 81: 4736-4750.

[14] KnudsenKE, ScherHI. Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res. 2009; 15: 4792-4798.

[15] BluemnEG, Coleman IM, LucasJM, et al. Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling. Cancer Cell. 2017; 32: 474-489. e6.

[16] NiuY, Altuwaijri S, LaiKP, et al. Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci USA. 2008; 105: 12182-12187.

[17] JinR, YiY, YullFE, et al. NF-κB gene signature predicts prostate cancer progression. Cancer Res. 2014; 74: 2763-2772.

[18] Don-DoncowN, Marginean F, ColemanI, et al. Expression of STAT3 in prostate cancer metastases. Eur Urol. 2017; 71: 313-316.

[19] FernandoRI, Castillo MD, LitzingerM, HamiltonDH, PalenaC. IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells. Cancer Res. 2011; 71: 5296-5306.

[20] XuY, JossonS, FangF, et al. RelB enhances prostate cancer growth: implications for the role of the nuclear factor-kappaB alternative pathway in tumorigenicity. Cancer Res. 2009; 69: 3267-3271.

[21] YuG, ChengCJ, LinSC, et al. Organelle-derived acetyl-CoA promotes prostate cancer cell survival, migration, and metastasis via activation of calmodulin kinase II. Cancer Res. 2018; 78: 2490-2502.

[22] KimH, KimB, Il KimS, et al. S100A4 released from highly bone-metastatic breast cancer cells plays a critical role in osteolysis. Bone Res. 2019; 7: 30.

[23] KimB, JungS, KimH, et al. The role of S100A4 for bone metastasis in prostate cancer cells. BMC Cancer. 2021; 21: 137.

[24] LiuZ, MarKB, HannersNW, et al. A NIK-SIX signalling axis controls inflammation by targeted silencing of non-canonical NF-κB. Nature. 2019; 568: 249-253.

[25] ZhangY, ZhuS, DuY, et al. RelB upregulates PD-L1 and exacerbates prostate cancer immune evasion. J Exp Clin Cancer Res. 2022; 41: 66.

[26] KimS, ZhangY, TangS, et al. Optimizing live-animal bioluminescence imaging prediction of tumor burden in human prostate cancer xenograft models in SCID-NSG mice. Prostate. 2019; 79: 949-960.

[27] OoiLL, ZhengY, ZhouH, et al. Vitamin D deficiency promotes growth of MCF-7 human breast cancer in a rodent model of osteosclerotic bone metastasis. Bone. 2010; 47: 795-803.

[28] KuchimaruT, Kataoka N, NakagawaK, et al. A reliable murine model of bone metastasis by injecting cancer cells through caudal arteries. Nat Commun. 2018; 9: 2981.

[29] CildirG, LowKC, TergaonkarV. Noncanonical NF-κB signaling in health and disease. Trends Mol Med. 2016; 22: 414-429.

[30] LapointeS, PerryA, ButowskiNA. Primary brain tumours in adults. Lancet. 2018; 392: 432-446.

[31] WaughDJ, WilsonC. The interleukin-8 pathway in cancer. Clin Cancer Res. 2008; 14: 6735-6741.

[32] MalinenM, Niskanen EA, KaikkonenMU, PalvimoJJ. Crosstalk between androgen and pro-inflammatory signaling remodels androgen receptor and NF-κB cistrome to reprogram the prostate cancer cell transcriptome. Nucleic Acids Res. 2017; 45: 619-630.

[33] TanC, HuW, HeY, et al. Cytokine-mediated therapeutic resistance in breast cancer. Cytokine. 2018; 108: 151-159.

[34] OliveraI, Sanz-Pamplona R, BolañosE, et al. A therapeutically actionable protumoral axis of cytokines involving IL-8, TNFα, and IL-1β. Cancer Discov. 2022; 12: 2140-2157.

[35] YuenKC, LiuLF, GuptaV, et al. High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade. Nat Med. 2020; 26: 693-698.

[36] MarinoS, BishopRT, CarrascoG, Logan JG, LiB, IdrisAI. Pharmacological inhibition of NFκB reduces prostate cancer related osteoclastogenesis in vitro and osteolysis ex vivo. Calcif Tissue Int. 2019; 105: 193-204.

[37] MakinoT, IzumiK, MizokamiA. Undesirable status of prostate cancer cells after intensive inhibition of AR signaling: post-AR era of CRPC treatment. Biomedicines. 2021; 9: 414.

[38] VellkyJE, RickeWA. Development and prevalence of castration-resistant prostate cancer subtypes. Neoplasia. 2020; 22: 566-575.

[39] RyeomS, BaekKH, RiothMJ, et al. Targeted deletion of the calcineurin inhibitor DSCR1 suppresses tumor growth. Cancer Cell. 2008; 13: 420-431.

[40] HoPC, Bihuniak JD, MacintyreAN, et al. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. Cell. 2015; 162: 1217-1228.

[41] GanaieAA, Mansini AP, HussainT, et al. Anti-S100A4 antibody therapy is efficient in treating aggressive prostate cancer and reversing immunosuppression: serum and biopsy S100A4 as a clinical predictor. Mol Cancer Ther. 2020; 19: 2598-2611.

[42] SchalperKA, Carleton M, ZhouM, et al. Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors. Nat Med. 2020; 26: 688-692.

[43] TiedemannK, Hussein O, KomarovaSV. Role of altered metabolic microenvironment in osteolytic metastasis. Front Cell Dev Biol. 2020; 8: 435.

[44] HuangZ, TangB, YangY, et al. MAP3K7-IKK inflammatory signaling modulates AR protein degradation and prostate cancer progression. Cancer Res. 2021; 81: 4471-4484.

[45] JinR, Yamashita H, YuX, et al. Inhibition of NF-kappa B signaling restores responsiveness of castrate-resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor-variant expression. Oncogene. 2015; 34: 3700-3710.

[46] MorelKL, HamidAA, ClohessyJG, Pandell N, EllisL, SweeneyCJ. NF-κB blockade with oral administration of dimethylaminoparthenolide (DMAPT), delays prostate cancer resistance to androgen receptor (AR) inhibition and inhibits AR variants. Mol Cancer Res. 2021; 19: 1137-1145.

[47] KoS, ShiL, KimS, SongCS, ChatterjeeB. Interplay of nuclear factor-kappaB and B-myb in the negative regulation of androgen receptor expression by tumor necrosis factor alpha. Mol Endocrinol. 2008; 22: 273-286.

[48] GrossetAA, Ouellet V, CaronC, et al. Validation of the prognostic value of NF-κB p65 in prostate cancer: a retrospective study using a large multi-institutional cohort of the Canadian Prostate Cancer Biomarker Network. PLoS Med. 2019; 16: e1002847.

[49] PuisieuxA, Brabletz T, CaramelJ. Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol. 2014; 16: 488-494.

[50] LüöndF, Sugiyama N, BillR, et al. Distinct contributions of partial and full EMT to breast cancer malignancy. Dev Cell. 2021; 56: 3203-3221. e11.

[51] BrabletzS, Schuhwerk H, BrabletzT, StemmlerMP. Dynamic EMT: a multi-tool for tumor progression. EMBO J. 2021; 40: e108647.

[52] YangMH, ChenCL, ChauGY, et al. Comprehensive analysis of the independent effect of twist and snail in promoting metastasis of hepatocellular carcinoma. Hepatology. 2009; 50: 1464-1474.

[53] TaubeJH, Herschkowitz JI, KomurovK, et al. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci USA. 2010; 107: 15449-15454.

[54] ZhengX, Carstens JL, KimJ, et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature. 2015; 527: 525-530.

[55] ZhouY, ShurinGV, ZhongH, Bunimovich YL, HanB, ShurinMR. Schwann cells augment cell spreading and metastasis of lung cancer. Cancer Res. 2018; 78: 5927-5939.

[56] DemirkanB. The roles of epithelial-to-mesenchymal transition (EMT) and mesenchymal-to-epithelial transition (MET) in breast cancer bone metastasis: potential targets for prevention and treatment. J Clin Med. 2013; 2: 264-282.

[57] GöbelA, Dell’Endice S, JaschkeN, et al. The role of inflammation in breast and prostate cancer metastasis to bone. Int J Mol Sci. 2021; 22: 5078.

[58] KorkayaH, KimGI, DavisA, et al. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell. 2012; 47: 570-584.

[59] RokavecM, Öner MG, LiH, et al. IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. Journal Clin Invest. 2014; 124: 1853-1867.

[60] FousekK, HornLA, PalenaC. Interleukin-8: a chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression. Pharmacol Ther. 2021; 219: 107692.

[61] Ishay-RonenD, Diepenbruck M, KalathurRKR, et al. Gain fat-lose metastasis: converting invasive breast cancer cells into adipocytes inhibits cancer metastasis. Cancer Cell. 2019; 35: 17-32. e6.

[62] ClézardinP, Coleman R, PuppoM, et al. Bone metastasis: mechanisms, therapies, and biomarkers. Physiol Rev. 2021; 101: 797-855.

[63] FornettiJ, WelmAL, StewartSA. Understanding the bone in cancer metastasis. J Bone Miner Res. 2018; 33: 2099-2113.

[64] LiuH, HeJ, Bagheri-YarmandR, et al. Osteocyte CIITA aggravates osteolytic bone lesions in myeloma. Nat Commun. 2022; 13: 3684.

[65] LynchCC. Matrix metalloproteinases as master regulators of the vicious cycle of bone metastasis. Bone. 2011; 48: 44-53.

[66] WangS, LiGX, TanCC, et al. FOXF2 reprograms breast cancer cells into bone metastasis seeds. Nat Commun. 2019; 10: 2707.

[67] LiJ, LiY, PengX, Li B, YuanX, ChenY. Emodin attenuates titanium particle-induced osteolysis and RANKL-mediated osteoclastogenesis through the suppression of IKK phosphorylation. Mol Immunol. 2018; 96: 8-18.

[68] IkebuchiY, AokiS, HonmaM, et al. Coupling of bone resorption and formation by RANKL reverse signalling. Nature. 2018; 561: 195-200.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.